FR2835835B1 - Nouveaux derives de la pyridazine, leur utilisation comme medicaments, compositions pharmaceutiques et leur procede de preparation - Google Patents

Nouveaux derives de la pyridazine, leur utilisation comme medicaments, compositions pharmaceutiques et leur procede de preparation

Info

Publication number
FR2835835B1
FR2835835B1 FR0201632A FR0201632A FR2835835B1 FR 2835835 B1 FR2835835 B1 FR 2835835B1 FR 0201632 A FR0201632 A FR 0201632A FR 0201632 A FR0201632 A FR 0201632A FR 2835835 B1 FR2835835 B1 FR 2835835B1
Authority
FR
France
Prior art keywords
medicaments
pharmaceutical compositions
preparation process
pyridazine derivatives
novel pyridazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0201632A
Other languages
English (en)
French (fr)
Other versions
FR2835835A1 (fr
Inventor
Neerja Bhatnagar
Didier Benard
Jean Francois Gourvest
Jacques Mauger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0201632A priority Critical patent/FR2835835B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to DK03717380T priority patent/DK1476434T3/da
Priority to SI200330424T priority patent/SI1476434T1/sl
Priority to JP2003567325A priority patent/JP4447324B2/ja
Priority to CA002475439A priority patent/CA2475439A1/fr
Priority to AT03717380T priority patent/ATE329907T1/de
Priority to AU2003222363A priority patent/AU2003222363A1/en
Priority to PT03717380T priority patent/PT1476434E/pt
Priority to ES03717380T priority patent/ES2266806T3/es
Priority to PCT/FR2003/000381 priority patent/WO2003068140A2/fr
Priority to DE60306122T priority patent/DE60306122T2/de
Priority to MXPA04007186A priority patent/MXPA04007186A/es
Priority to BR0307565-6A priority patent/BR0307565A/pt
Priority to EP03717380A priority patent/EP1476434B1/fr
Publication of FR2835835A1 publication Critical patent/FR2835835A1/fr
Application granted granted Critical
Publication of FR2835835B1 publication Critical patent/FR2835835B1/fr
Priority to US10/916,175 priority patent/US7223758B2/en
Priority to CY20061101281T priority patent/CY1107483T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR0201632A 2002-02-11 2002-02-11 Nouveaux derives de la pyridazine, leur utilisation comme medicaments, compositions pharmaceutiques et leur procede de preparation Expired - Fee Related FR2835835B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR0201632A FR2835835B1 (fr) 2002-02-11 2002-02-11 Nouveaux derives de la pyridazine, leur utilisation comme medicaments, compositions pharmaceutiques et leur procede de preparation
DE60306122T DE60306122T2 (de) 2002-02-11 2003-02-07 Pyridazinderivate, deren verwendung als heilmittel, und deren verfahren zu ihrer verwendung
JP2003567325A JP4447324B2 (ja) 2002-02-11 2003-02-07 新規なピリダジン誘導体、医薬としてのその使用、その医薬組成物および製造方法
CA002475439A CA2475439A1 (fr) 2002-02-11 2003-02-07 Derives de la pyridazine, leur utilisation comme medicaments, et leur procede de preparation
AT03717380T ATE329907T1 (de) 2002-02-11 2003-02-07 Pyridazinderivate, deren verwendung als heilmittel, und deren verfahren zu ihrer verwendung
AU2003222363A AU2003222363A1 (en) 2002-02-11 2003-02-07 Novel pyridazine derivatives, uses of the same as medicaments, pharmaceutical compositions and method for producing the same
PT03717380T PT1476434E (pt) 2002-02-11 2003-02-07 Derivados de piridazina, sua utilizacao como medicamentos e seu processo de preparacao
ES03717380T ES2266806T3 (es) 2002-02-11 2003-02-07 Derivados de piridazina, su utilizacion como medicamentos y su procedimiento de preparacion.
DK03717380T DK1476434T3 (da) 2002-02-11 2003-02-07 Pyridazinderivater, deres anvendelse som lægemidler og fremgangsmåde til deres fremstiling
SI200330424T SI1476434T1 (sl) 2002-02-11 2003-02-07 Derivati piridazina, njihova uporaba kot zdravilain postopek za njihovo pripravo
MXPA04007186A MXPA04007186A (es) 2002-02-11 2003-02-07 Nuevos derivados de la piridazina, su utilizacion como medicamentos, composiciones farmaceuticas y su procedimiento de preparacion.
BR0307565-6A BR0307565A (pt) 2002-02-11 2003-02-07 Derivados da piridazina, sua utilização como medicamentos, composições farmacêuticas e seu processo de preparação
EP03717380A EP1476434B1 (fr) 2002-02-11 2003-02-07 Derives de la pyridazine, leur utilisation comme medicaments, et leur procede de preparation
PCT/FR2003/000381 WO2003068140A2 (fr) 2002-02-11 2003-02-07 Derives de la pyridazine, leur utilisation comme medicaments, et leur procede de preparation
US10/916,175 US7223758B2 (en) 2002-02-11 2004-08-11 Pyridazine derivative, pharmaceutical composition thereof, its pharmaceutical use, and process for its preparation
CY20061101281T CY1107483T1 (el) 2002-02-11 2006-09-07 Παραγωγα πυριδαζινης, η χρηση τους ως φαρμακευτικα σκευασματα και η διαδικασια παρασκευης τους

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0201632A FR2835835B1 (fr) 2002-02-11 2002-02-11 Nouveaux derives de la pyridazine, leur utilisation comme medicaments, compositions pharmaceutiques et leur procede de preparation

Publications (2)

Publication Number Publication Date
FR2835835A1 FR2835835A1 (fr) 2003-08-15
FR2835835B1 true FR2835835B1 (fr) 2004-04-16

Family

ID=27620073

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0201632A Expired - Fee Related FR2835835B1 (fr) 2002-02-11 2002-02-11 Nouveaux derives de la pyridazine, leur utilisation comme medicaments, compositions pharmaceutiques et leur procede de preparation

Country Status (15)

Country Link
US (1) US7223758B2 (enExample)
EP (1) EP1476434B1 (enExample)
JP (1) JP4447324B2 (enExample)
AT (1) ATE329907T1 (enExample)
AU (1) AU2003222363A1 (enExample)
BR (1) BR0307565A (enExample)
CA (1) CA2475439A1 (enExample)
CY (1) CY1107483T1 (enExample)
DE (1) DE60306122T2 (enExample)
DK (1) DK1476434T3 (enExample)
ES (1) ES2266806T3 (enExample)
FR (1) FR2835835B1 (enExample)
MX (1) MXPA04007186A (enExample)
PT (1) PT1476434E (enExample)
WO (1) WO2003068140A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2839309B1 (fr) * 2002-05-03 2004-07-23 Aventis Pharma Sa Nouveaux derives de l'acide hexahydro-pyridazine-3- carboxylique, chimiotheques les contenant, leur utilisation comme medicaments, compositions pharmaceutiques les contenant et leurs procedes de preparation
EP1851204A1 (en) * 2005-02-23 2007-11-07 SmithKline Beecham Corporation Naphthalene derivatives as modulators of the glucocorticoid receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE191713T1 (de) * 1991-11-08 2000-04-15 Sankyo Co Piperazin derivate als collagenase inhibitoren

Also Published As

Publication number Publication date
WO2003068140A3 (fr) 2004-04-08
CY1107483T1 (el) 2013-03-13
EP1476434A2 (fr) 2004-11-17
AU2003222363A1 (en) 2003-09-04
CA2475439A1 (fr) 2003-08-21
DE60306122T2 (de) 2007-06-06
JP4447324B2 (ja) 2010-04-07
EP1476434B1 (fr) 2006-06-14
DE60306122D1 (de) 2006-07-27
US7223758B2 (en) 2007-05-29
US20050165017A1 (en) 2005-07-28
JP2005525334A (ja) 2005-08-25
WO2003068140A2 (fr) 2003-08-21
FR2835835A1 (fr) 2003-08-15
PT1476434E (pt) 2006-10-31
ATE329907T1 (de) 2006-07-15
MXPA04007186A (es) 2004-10-29
BR0307565A (pt) 2004-12-21
ES2266806T3 (es) 2007-03-01
DK1476434T3 (da) 2006-10-16

Similar Documents

Publication Publication Date Title
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
JO2707B1 (ar) مشتقات ثيوفين جليكوسايد جديدة, طرق تحضيرها, والادوية المحتوية على هذه المركبات واستخدامها
MY142029A (en) Phenoxyacetic acid derivatives
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
WO2003084922A8 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
GB0313612D0 (en) Organic compounds
MEP9309A (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing the same
MY147262A (en) 1-aza-bicyclo[3.3.1]nonanes
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
NZ515108A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
SG146627A1 (en) Imidazole derivatives
ATE284882T1 (de) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
FR2835835B1 (fr) Nouveaux derives de la pyridazine, leur utilisation comme medicaments, compositions pharmaceutiques et leur procede de preparation
DE60119514D1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentansäure
BRPI0408148A (pt) derivados de ácido benzoilureidopiridil-piperidina e -pirrolidina-carboxìlico, processos para a preparação e uso dos mesmos
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
FR2784682B1 (fr) Nouveaux derives 2-halogene de 5-0-desosaminylerythronolide a, leur procede de preparation et leur application comme medicaments
WO2003004460A3 (en) Succinic acid derivatives
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20151030